Literature DB >> 8843861

Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy.

A A Grom1, K J Murray, L Luyrink, H Emery, M H Passo, D N Glass, T Bowlin, C Edwards.   

Abstract

OBJECTIVE: To assess the expression of tumor necrosis factor alpha (TNF alpha), TNF beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis (JRA) and juvenile spondylarthropathy (JSpA), and to determine similarities with and differences from adult RA.
METHODS: Twenty-eight synovial tissue samples from patients with JRA, 6 from patients with JSpA, and 6 from patients with RA, selected for the presence of inflammatory infiltrates, were analyzed for the expression of TNF alpha, TNF beta, and their receptors (p55 and p75 TNFR), utilizing the dual approach of reverse transcriptase-polymerase chain reaction and immunohistochemistry analysis.
RESULTS: The presence of both TNF alpha and TNF beta expression was demonstrated in most JRA and JSpA tissues, although samples from patients with pauciarticular JRA had somewhat lesser amounts of these cytokines. TNF beta expression correlated significantly with the occurrence of lymphocytic aggregates in tissues. Staining with monoclonal antibodies specific for the p55 and p75 receptors revealed that a diverse range of cell types expressed the receptors, with the most intense p55 staining on vascular endothelial cells. In the vast majority of synovial tissues, far greater numbers of cells expressed the p55 form of the receptor than the p75 form.
CONCLUSION: JRA and JSpA synovia are characterized by the presence of TNF alpha, TNF beta, and cells expressing TNFR. These findings provide further evidence that TNF, through autocrine/paracrine mechanisms, may amplify local inflammation, leading to joint destruction. The prominence of TNF beta in the synovium in particular subgroups of JRA patients and in JSpA patients may be a distinguishing feature of these diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843861     DOI: 10.1002/art.1780391013

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

Review 2.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 3.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  In vivo expression of inflammatory cytokine receptors in the joint compartments of patients with arthritis.

Authors:  Tania Silvestri; Lia Pulsatelli; Paolo Dolzani; Luigi Frizziero; Andrea Facchini; Riccardo Meliconi
Journal:  Rheumatol Int       Date:  2005-03-16       Impact factor: 2.631

Review 5.  Advances from clinical trials in juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Nicola Ruperto; Edward H Giannini; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2013-07-09       Impact factor: 20.543

Review 6.  Juvenile onset spondyloarthropathies: therapeutic aspects.

Authors:  R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

7.  A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China.

Authors:  Dawei Hu; Chunde Bao; Shunle Chen; Jieruo Gu; Zhanguo Li; Lingyun Sun; Xinghai Han; Liqing Ni
Journal:  Rheumatol Int       Date:  2008-08-15       Impact factor: 2.631

8.  Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.

Authors:  D Windschall; T Müller; I Becker; G Horneff
Journal:  Clin Rheumatol       Date:  2014-07-18       Impact factor: 2.980

9.  Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Authors:  A Calin; B A C Dijkmans; P Emery; M Hakala; J Kalden; M Leirisalo-Repo; E M Mola; C Salvarani; R Sanmartí; J Sany; J Sibilia; J Sieper; S van der Linden; E Veys; A M Appel; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

10.  Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.

Authors:  Ruy Carrasco; Judith A Smith; Daniel Lovell
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.